Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate Cancer Taxotere(R)-based regimen is the first and...
Investigators Report Taxotere(R) Offers Significant Survival Benefits for Head and Neck Cancer Patients BRIDGEWATER, N.J., June 5...
Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers PARIS, June 1 /PRNewswire-FirstCall/ -- On June 1, 2004, the Autorite des marches...
Genta and Aventis Announce Termination of Genasense(TM) Expanded Access Program in Melanoma BERKELEY HEIGHTS and BRIDGEWATER, N.J., May 28...
Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine Agreement World's Largest Vaccine Developer to Produce Investigational Vaccine...
Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004 PARIS, May 26 /PRNewswire-FirstCall/ -- Sanofi-Synthelabo...
Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary Session BRIDGEWATER, N.J...
Surveillance Study Finds Newly-Approved Antibiotic KETEK(R) (telithromycin) Tablets 99% Effective In Vitro Against Streptococcus...
Aventis Receives FDA Approval for Taxotere(R) in Prostate Cancer BRIDGEWATER, N.J., May 19 /PRNewswire-FirstCall/ -- Aventis announced...
Aventis Receives Priority Review Designation for the Registrational Application to Support the Use of Taxotere(R) in Women with Early-Stage Breast...
Sanofi-Synthelabo's Offer for Aventis Request for Additional Information from the Federal Trade Commission PARIS, May 5 /PRNewswire-FirstCall/...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced Melanoma BERKELEY HEIGHTS, N.J. and BRIDGEWATER, N.J., May 3...
Aventis Pasteur Statement on New Influenza Immunization Recommendations for Infants, Young Children and Their Close Contacts SWIFTWATER, Pa...
Aventis Reports First-Quarter Results for 2004 All Figures Refer to 2004 Group vs 2003 Core Unless Otherwise Stated STRASBOURG, France, April 29...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads